CClinicalTrials.gg
RecruitingNCT07566260Updated Sep 9, 2026

Stress and Menstrual Health

An interventional study of Heat stress and Sleep stress in Menstrual Dysfunction, sponsored by Duke University. Recruiting at 1 site in United States. Open to female participants aged 22 Years to 38 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Duke University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Non-randomized
Ages
22 Years to 38 Years
Sex
Female
01

Study summary

The goal of this experimental study is to determine how stressors that do not directly impact energy state or energy demands (hereafter called "non-energetic stressors") affect reproductive health in pre-menopausal women. It aims to do this by answering the following main questions: Do non-energetic stressors create a stress response? How does the stress response impact sex hormone concentration and thus menstrual dysfunction? If stress caused by non-energetic stressors does impact sex hormone concentration, does it do so primarily at the level of the brain or the level of the ovary? Participants will be enrolled in this study for 6 months. For two of these months, they will undergo a short stress intervention and provide samples to measure hormone concentration and total energy expenditure.

Read the detailed description

The Reproductive Suppression Model posits that due to the high cost and failure rate of human reproduction, the female body maximizes lifetime reproductive fitness by suppressing reproduction during poor conditions (where likelihood of offspring survival is low) until conditions are more favorable. The hormonal mechanism for this suppression when calories are scarce and the female body is in low energy availability (LEA) has been studied. However, the mechanism for this suppression in the presence of stressors unrelated to low energy availability, but which could still negatively impact offspring survival, is much less clear. The investigators define such stressors, which do not impact energy state or energetic demands, as "non-energetic stressors." Thus, the aim of this study is to determine if non-energetic stressors drive reproductive suppression in humans. The investigators will assess this by testing the impact of a stress intervention on the stress hormones cortisol and norepinephrine, and in turn if the levels of these stress hormones predict the levels of sex hormones associated with the menstrual cycle. Finally, the investigators will assess if changes in stress hormones change total and basal energy expenditure.

02

Conditions studied

  • Menstrual Dysfunction

Keywords

  • Stress
  • Menstruation
  • Energy Expenditure
03

In context

Lead sponsor

Duke University is the lead sponsor of 2,025 studies on the registry; 275 are open to participants now.

Of its 194 completed or terminated interventional studies of FDA-regulated products, 159 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 38 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Adult pre-menopausal females, 22-38 years old with a BMI of 18.5-30.0
  • Habitually sedentary (less than 60 minutes MVPA/week) for Exercise cohort

Exclusion criteria

Exclusion Criteria:

  • Individuals on hormonal birth control (oral contraception, injection, implant, or intrauterine device)
  • Individuals with incidence in the last 6 months of childbirth, lactation, pregnancy, or functional hypothalamic amenorrhea (FHA)
  • Individuals with a BMI \<18.5 or >30.0
  • Individuals with reproductive disorders (e.g. endometriosis, polycystic ovarian syndrome (PCOS))
  • Individuals taking thyroid medications
  • Individuals who have undergone or are undergoing menopause
  • MVPA >60 min/week (for Exercise cohort)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Heat Stress

    Heat stress via 70-80°C sauna exposure for 45-min sessions on 5 consecutive days (days 4-8 or 5-9 of follicular phase).

    Other: Heat stress

  • Experimental
    Sleep Stress

    Sleep restriction to 4-6 hours/night for 5 consecutive nights (on days 3-8 or 4-9 of follicular phase).

    Other: Sleep stress

  • Experimental
    Exercise Stress

    One-hour cycling at 60-75% predicted max HR for 5 consecutive days (days 4-8 or 5-9 of follicular phase).

    Other: Exercise stress

Interventions

  • OtherHeat stress

    Stress-Heat participants will undergo supervised 40-min sessions in a 70-80˚C sauna

  • OtherSleep stress

    Stress-Sleep participants will be asked to sleep for between 4 and 6 hours per night, with compliance monitored via their activity monitors and self-reported sleep diaries. Participants will be requested to maintain normal wake cycles without midday sleep.

  • OtherExercise stress

    Stress-Exercise participants will come to the Pontzer Lab to complete a one-hour cycling workout on a Lode Corival CPET ergometer/exercise bike at 60-75% predicted maximum heart rate.

06

What researchers measure

Primary outcomes

  1. Total daily energy expenditure (TDEE)

    TDEE (kcal) will be measured over a 7-day period during the Baseline and first Intervention month using the doubly-labeled water (DLW) method. DLW is a safe and reliable method for capturing free-living TDEE and has been validated for human studies. The DLW method adds a known amount of stable isotopes, oxygen-18 (18O) and deuterium (2H), to a participant's total body water (TBW) via ingestion and then measures the depletion rate of these isotopes as they are removed from the body via urine and exhalation.

    Time frame: Control (Month 3), Intervention (Month 4)

  2. Basal metabolic rate (BMR)

    BMR (kcal/d) will be estimated via indirect calorimetry. Participants will be asked to come in for a lab visit on a day of their choice within 2-7 days post-ovulation prior to consuming breakfast or any non-water beverage and after having refrained from exercise for 24 hours pre-measurement. Participants will lie on an exam bed in the Pontzer Lab and have a clear plastic hood connected to a COSMED Quark RMR machine placed over their head for approximately 25-30 minutes. This hood will collect exhaled air, which will be measured for CO2 production to estimate BMR.

    Time frame: Baseline (Month 2), Control (Month 3), Intervention (Months 4-5), and Follow-up (Month 6)

  3. Sex hormone concentration (estradiol)

    Samples will be assayed via enzyme-linked immunosorbent assay (ELISA) in the Pontzer Lab.

    Time frame: Baseline (Month 2), Control (Month 3), Intervention (Months 4-5), and Follow-up (Month 6)

  4. Sex hormone concentration (progesterone)

    Samples will be assayed via enzyme-linked immunosorbent assay (ELISA) in the Pontzer Lab.

    Time frame: Baseline (Month 2), Control (Month 3), Intervention (Months 4-5), and Follow-up (Month 6)

Secondary outcomes

  1. Stress hormone concentration (norepinephrine)

    Samples will be assayed via enzyme-linked immunosorbent assay (ELISA) in the Pontzer Lab.

    Time frame: Baseline (Month 2), Control (Month 3), Intervention (Months 4-5), and Follow-up (Month 6)

  2. Stress hormone concentration (cortisol)

    Samples will be assayed via enzyme-linked immunosorbent assay (ELISA) in the Pontzer Lab.

    Time frame: Baseline (Month 2), Control (Month 3), Intervention (Months 4-5), and Follow-up (Month 6)

  3. Stress hormone concentration (salivary alpha-amylase)

    Samples will be assayed via enzyme-linked immunosorbent assay (ELISA) in the Pontzer Lab.

    Time frame: Baseline (Month 2), Control (Month 3), Intervention (Months 4-5), and Follow-up (Month 6)

  4. Sex hormone concentration (luteinizing hormone (LH))

    Samples will be assayed via enzyme-linked immunosorbent assay (ELISA) in the Pontzer Lab.

    Time frame: Baseline (Month 2), Control (Month 3), Intervention (Months 4-5), and Follow-up (Month 6)

  5. Sex hormone concentration (follicle-stimulating hormone (FSH))

    Samples will be assayed via enzyme-linked immunosorbent assay (ELISA) in the Pontzer Lab.

    Time frame: Baseline (Month 2), Control (Month 3), Intervention (Months 4-5), and Follow-up (Month 6)

07

Study locations

1 of 1 sites recruiting
  • Duke University
    Durham, North Carolina 27708, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07566260
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
May 5, 2026
Start date
May 28, 2026
Primary completion
Aug 2028 (estimated)
Completion
Aug 2029 (estimated)
Last update
Sep 9, 2026

Study contacts

Herman Pontzer, PhD
principal investigator · Duke University Evolutionary Anthropology Department

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion